Long term dosing of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds

TW202641558APending Publication Date: 2026-10-16TAURX THERAPEUTICS MANAGEMENT LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114152129
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-01-02
Filing Date
2025-12-31
Publication Date
2026-10-16

Smart Images

  • Figure TWG2TA001080845_001
    Figure TWG2TA001080845_001
  • Figure TWG2TA001080845_002
    Figure TWG2TA001080845_002
  • Figure TWG2TA001080845_003
    Figure TWG2TA001080845_003
Patent Text Reader

Abstract

present invention is provides a method of treatment of a neurodegenerative disease such Alzheimer's Disease (AD), or mild cognitive impairment due to AD, as in a subject, which method comprises orally administering to said subject a methylthioninium (MT) compound, at a first dosage level for a first dosage period and then at a second dosage level for a second dosage period wherein the second dosage level is higher than the first dosage level, and wherein the first dosage period is between
Need to check novelty before this filing date? Find Prior Art